"10.1371_journal.pmed.1001061","plos medicine","2011-07-26T00:00:00Z","Lesley E Scott; Kerrigan McCarthy; Natasha Gous; Matilda Nduna; Annelies Van Rie; Ian Sanne; Willem F Venter; Adrian Duse; Wendy Stevens","Department of Molecular Medicine and Hematology, University of the Witwatersrand, Johannesburg, South Africa; Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa; National Health Laboratory Service, Johannesburg, South Africa; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; Clinical HIV Research Unit, Department of Medicine, University of the Witwatersrand, and Right to Care, Johannesburg, South Africa; Department of Clinical Microbiology and Infectious Diseases, University of the Witwatersrand, Johannesburg, South Africa","Conceived and designed the experiments: LS KM WS IS FV AD. Performed the experiments: NG LS. Analyzed the data: LS KM AVR NG. Contributed reagents/materials/analysis tools: WS IS FV. Wrote the paper: LS KM AVR NG WS. ICMJE criteria for authorship read and met: LS KM NG MN AVR IS FV AD WS. Agree with the manuscripts results and conclusions: LS KM NG MN AVR IS FV AD WS. Enrolled patients: MN. Wrote the first draft of the paper: LS KM NG WS. Clinic management where study conducted: FV IS. Managed infection control necessary for study to be performed and assistance with RIF resistance data interpretation: AD.","The Academic Editor, Madhukar Pai, declares that he consults for the Bill & Melinda Gates Foundation (BMGF). The BMGF supported the Foundation for Innovative New Diagnostics (FIND), which was involved in the development of the Xpert MTB/RIF assay. He also co-chairs the Stop TB Partnerships New Diagnostics Working Group that was involved in the WHO endorsement of the Xpert assay. The authors have declared that no competing interests exist.","2011","07","Lesley E Scott","LES",9,FALSE,6,2,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
